Format

Send to

Choose Destination
J Pharm Biomed Anal. 2015 Mar 25;107:63-74. doi: 10.1016/j.jpba.2014.12.020. Epub 2014 Dec 22.

Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery.

Author information

1
Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego 92182, USA. Electronic address: seemabiotech83@gmail.com.
2
Institute of Bioinformatics and Biotechnology, Savitribai Phule Pune University, Pune 411007, India.

Abstract

Most cancers are lethal and metabolic alterations are considered a hallmark of this deadly disease. Genomics and proteomics have contributed vastly to understand cancer biology. Still there are missing links as downstream to them molecular divergence occurs. Metabolomics, the omic science that furnishes a dynamic portrait of metabolic profile is expected to bridge these gaps and boost cancer research. Metabolites being the end products are more stable than mRNAs or proteins. Previous studies have shown the efficacy of metabolomics in identifying biomarkers associated with diagnosis, prognosis and treatment of cancer. Metabolites are highly informative about the functional status of the biological system, owing to their proximity to organismal phenotypes. Scores of publications have reported about high-throughput data generation by cutting-edge analytic platforms (mass spectrometry and nuclear magnetic resonance). Further sophisticated statistical softwares (chemometrics) have enabled meaningful information extraction from the metabolomic data. Metabolomics studies have demonstrated the perturbation in glycolysis, tricarboxylic acid cycle, choline and fatty acid metabolism as traits of cancer cells. This review discusses the latest progress in this field, the future trends and the deficiencies to be surmounted for optimally implementation in oncology. The authors scoured through the most recent, high-impact papers archived in Pubmed, ScienceDirect, Wiley and Springer databases to compile this review to pique the interest of researchers towards cancer metabolomics.

KEYWORDS:

Biomarker; Cancer; Mass spectrometry; Metabolomics; Nuclear magnetic resonance

PMID:
25569286
DOI:
10.1016/j.jpba.2014.12.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center